Engineered Immunoagonist Non-Coding RNA (incRNA) Activates Dual TLR Pathways for Cancer Immunotherapy.

Area of Science:

• Immunology
• RNA Therapeutics
• Oncology

Background:

• Conventional mRNA therapeutics focus on minimizing immunogenicity.
• Immunogenicity can be therapeutically advantageous.
• Extensive mRNA modification may not be universally necessary.

Purpose of the Study:

• Introduce immunoagonist non-coding RNA (incRNA) as a new therapeutic class.
• Exploit innate immune activation via RNA.
• Challenge the need for universal mRNA modification.

Main Methods:

• In vitro transcription of incRNA from non-coding DNA templates without modified nucleotides.
• Lipid nanoparticle (LNP) encapsulation and delivery of incRNA.
• In vitro assessment of immune cell reprogramming (macrophage repolarization, dendritic cell maturation).
• In vivo studies in a melanoma mouse model, including combination therapy with anti-PD-1.

Main Results:

• incRNA robustly induced immunogenic reprogramming in vitro.
• Potent dual pattern recognition: >20-fold TLR3/interferon (dsRNA) and sixfold TLR7/TNF-α (ssRNA) signaling.
• In vivo incRNA delivery promoted innate and adaptive immune cell recruitment.
• Significant tumor regression observed in melanoma models.
• Enhanced immune recruitment when combined with anti-PD-1 checkpoint inhibition.

Conclusions:

• RNA therapeutics' efficacy is context-dependent.
• Leveraging intrinsic RNA immunogenicity can amplify therapeutic effects.
• incRNA represents a promising strategy for harnessing innate immunity in cancer therapy.